Phibro Animal Health (PAHC) Financials

$34.18 -0.19 (-0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$34.34 +0.16 (+0.45%)

As of 07:55 PM Eastern

Annual Income Statements for Phibro Animal Health

This table shows Phibro Animal Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	60	83	65	65	55	34	54	49	33	2.42	48
Consolidated Net Income / (Loss)	60	83	65	65	55	34	54	49	33	2.42	48
Net Income / (Loss) Continuing Operations	60	83	65	65	55	34	54	49	33	2.42	48
Total Pre-Tax Income	79	77	81	88	72	56	66	72	54	11	68
Total Operating Income	88	86	98	99	83	69	75	79	72	53	110
Total Gross Profit	233	239	248	267	265	257	271	285	298	313	400
Total Revenue	749	752	764	820	828	800	833	942	978	1,018	1,296
Operating Revenue	749	752	764	820	828	800	833	942	978	1,018	1,296
Total Cost of Revenue	515	512	516	553	563	543	562	657	680	705	896
Operating Cost of Revenue	515	512	516	553	563	543	562	657	680	705	896
Total Operating Expenses	146	153	150	168	181	188	197	206	226	260	289
Selling, General & Admin Expense	146	153	150	168	181	188	197	206	226	260	289
Total Other Income / (Expense), net	-8.91	-8.98	-17	-11	-12	-14	-8.40	-6.66	-18	-42	-42
Interest & Investment Income	-	-	-	-	-	-	-	-12	-15	-19	-35
Other Income / (Expense), net	5.40	7.61	0.11	1.05	0.06	-0.83	4.48	5.22	-2.46	-24	-7.87
Income Tax Expense	18	-5.97	16	23	17	22	12	23	21	8.50	20
Basic Earnings per Share	$1.55	$2.11	$1.63	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06	$1.19
Weighted Average Basic Shares Outstanding	38.97M	39.25M	39.52M	40.18M	40.41M	40.45M	40.47M	40.50M	40.50M	40.50M	40.52M
Diluted Earnings per Share	$1.51	$2.07	$1.61	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06	$1.19
Weighted Average Diluted Shares Outstanding	39.82M	39.96M	40.04M	40.39M	40.52M	40.50M	40.50M	40.50M	40.50M	40.52M	40.68M
Weighted Average Basic & Diluted Shares Outstanding	38.90M	39.20M	39.60M	40.30M	40.45M	40.45M	40.50M	40.50M	40.50M	40.50M	40.53M
Cash Dividends to Common per Share	$0.40	$0.40	$0.40	$0.40	$0.46	$0.48	$0.48	$0.48	$0.48	$0.48	$0.48

This table shows Phibro Animal Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-8.02	1.27	8.41	0.75	6.98	3.19	21	17	27	27	24
Consolidated Net Income / (Loss)	-8.02	1.27	8.41	0.75	6.98	3.19	21	17	27	27	24
Net Income / (Loss) Continuing Operations	-8.02	1.27	8.41	0.75	6.98	3.19	21	17	27	27	24
Total Pre-Tax Income	-12	3.57	13	6.41	9.62	4.84	30	24	36	36	32
Total Operating Income	-0.73	16	20	18	18	26	34	34	51	50	45
Total Gross Profit	68	79	80	87	83	102	105	110	120	133	126
Total Revenue	231	250	263	273	260	309	348	379	364	374	384
Operating Revenue	231	250	263	273	260	309	348	379	364	374	384
Total Cost of Revenue	164	171	184	186	177	207	243	269	244	241	258
Operating Cost of Revenue	164	171	184	186	177	207	243	269	244	241	258
Total Operating Expenses	68	63	60	69	66	76	71	76	69	82	81
Selling, General & Admin Expense	68	63	60	69	66	76	71	76	69	82	81
Total Other Income / (Expense), net	-11	-12	-7.00	-12	-8.08	-21	-3.83	-9.87	-15	-14	-12
Interest & Investment Income	-4.56	-4.66	-4.58	-	-7.64	-9.00	-9.36	-8.61	-12	-12	-10
Other Income / (Expense), net	-6.69	-7.48	-2.43	-7.27	-0.44	-12	5.53	-1.26	-2.93	-2.15	-1.91
Income Tax Expense	-3.96	2.29	4.52	5.66	2.65	1.65	8.81	6.62	9.74	8.97	8.29
Basic Earnings per Share	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08	$0.52	$0.42	$0.65	$0.68	$0.59
Weighted Average Basic Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.52M	40.52M	40.53M	40.53M	40.55M
Diluted Earnings per Share	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08	$0.51	$0.43	$0.65	$0.67	$0.59
Weighted Average Diluted Shares Outstanding	40.50M	40.50M	40.52M	40.52M	40.58M	40.72M	40.71M	40.68M	40.88M	40.96M	41.04M
Weighted Average Basic & Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.53M	40.53M	40.53M	40.53M	40.56M

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Change in Cash & Equivalents	17	4.39	22	-27	28	-21	14	24	-33	29	-2.57
Net Cash From Operating Activities	69	37	98	70	47	59	48	32	13	88	80
Net Cash From Continuing Operating Activities	69	37	98	70	47	59	48	32	13	88	79
Net Income / (Loss) Continuing Operations	60	83	65	65	55	34	54	49	33	2.42	48
Consolidated Net Income / (Loss)	60	83	65	65	55	34	54	49	33	2.42	48
Depreciation Expense	22	23	26	27	28	32	32	33	34	36	46
Amortization Expense	0.97	0.99	1.02	0.88	0.88	0.88	0.83	0.59	0.73	1.04	2.02
Non-Cash Adjustments To Reconcile Net Income	-1.96	-1.65	6.28	4.79	0.06	-1.90	-6.75	-5.38	-10	27	5.00
Changes in Operating Assets and Liabilities, net	-12	-68	0.48	-27	-36	-5.53	-32	-45	-44	21	-22
Net Cash From Investing Activities	-34	-83	-22	-85	-14	-120	-19	-23	-74	-48	-289
Net Cash From Continuing Investing Activities	-34	-83	-22	-85	-14	-120	-19	-23	-74	-48	-289
Purchase of Property, Plant & Equipment	-20	-36	-21	-19	-30	-34	-29	-37	-52	-41	-38
Acquisitions	-10	-47	-	-15	-9.84	-55	0.00	-14	0.00	-3.28	-287
Purchase of Investments	-	-	-	-82	-34	-80	-74	-64	-40	-66	-14
Sale and/or Maturity of Investments	-	-	-	32	60	49	86	91	17	62	49
Other Investing Activities, net	-4.03	0.14	-1.06	-1.06	-0.40	-0.80	-1.26	0.62	0.78	0.33	1.13
Net Cash From Financing Activities	-15	50	-54	-12	-4.11	41	-17	16	27	-6.77	207
Net Cash From Continuing Financing Activities	-15	50	-54	-12	-4.11	41	-17	16	27	-6.77	206
Repayment of Debt	-39	-193	-524	-226	-203	-183	-298	-256	-280	-263	-956
Payment of Dividends	-16	-16	-16	-16	-19	-19	-19	-19	-19	-19	-19
Issuance of Debt	38	256	481	225	217	243	300	297	326	276	1,182
Effect of Exchange Rate Changes	-1.49	-0.42	-0.23	-0.54	-0.52	-1.12	1.14	-1.37	0.75	-3.30	-1.14
Cash Interest Paid	13	14	15	11	12	12	11	11	15	17	32
Cash Income Taxes Paid	11	17	15	15	16	21	19	18	20	15	13

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	1.87	-10	17	20	-19	15	-6.72	7.69	4.73	-17	-0.56
Net Cash From Operating Activities	16	32	11	28	13	3.08	43	21	9.30	19	16
Net Cash From Continuing Operating Activities	16	32	11	28	13	3.08	43	20	9.30	19	16
Net Income / (Loss) Continuing Operations	-8.02	1.27	8.41	0.75	6.98	3.19	21	17	27	27	24
Consolidated Net Income / (Loss)	-8.02	1.27	8.41	0.75	6.98	3.19	21	17	27	27	24
Depreciation Expense	8.87	8.91	9.20	9.20	9.00	12	13	12	13	13	12
Amortization Expense	0.26	0.26	0.26	0.26	0.37	0.50	0.57	0.57	0.57	0.57	0.57
Non-Cash Adjustments To Reconcile Net Income	15	5.53	4.12	2.56	-0.80	13	1.28	-8.72	0.74	-0.32	2.21
Changes in Operating Assets and Liabilities, net	0.40	16	-11	16	-2.93	-25	7.81	-1.01	-31	-21	-23
Net Cash From Investing Activities	-15	-25	1.13	-9.11	-2.93	-260	-18	-7.03	-21	-17	-17
Net Cash From Continuing Investing Activities	-15	-25	1.13	-9.11	-2.93	-260	-18	-7.03	-21	-17	-17
Purchase of Property, Plant & Equipment	-7.48	-11	-9.73	-13	-9.58	-7.82	-7.75	-13	-14	-11	-15
Purchase of Investments	-17	-43	-6.00	-	0.00	-	-10	-4.00	-13	-12	-13
Sale and/or Maturity of Investments	9.00	31	17	4.52	6.00	38	-	5.00	9.00	5.00	9.50
Other Investing Activities, net	0.12	0.95	-0.18	-0.56	0.65	0.17	0.55	-0.24	-3.70	0.43	2.01
Net Cash From Financing Activities	1.30	-15	4.85	1.79	-29	276	-32	-7.77	16	-19	-2.30
Net Cash From Continuing Financing Activities	1.30	-15	4.85	1.79	-29	276	-32	-8.74	16	-19	-2.30
Repayment of Debt	-43	-50	-56	-114	-591	-198	-107	-62	-65	-76	-70
Payment of Dividends	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.87	-4.86	-4.86	-4.86	-4.87
Issuance of Debt	51	42	62	121	567	481	81	53	86	62	73
Effect of Exchange Rate Changes	-0.27	-2.18	-0.14	-0.72	0.73	-3.69	0.60	1.21	0.11	-0.47	2.34

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Total Assets	493	608	623	672	727	784	841	932	971	982	1,361
Total Current Assets	314	343	364	415	466	452	499	566	586	601	811
Cash & Equivalents	29	34	56	29	58	36	50	74	41	71	68
Short-Term Investments	-	-	-	50	24	55	43	17	40	44	9.00
Accounts Receivable	111	124	126	136	159	127	147	167	163	169	228
Inventories, net	150	168	161	178	198	197	216	259	278	266	444
Other Current Assets	24	18	21	22	27	37	43	49	63	51	61
Plant, Property, & Equipment, net	104	127	127	130	140	148	155	165	196	203	355
Total Noncurrent Assets	75	138	132	126	120	184	188	200	190	178	196
Goodwill	13	21	24	27	27	53	53	53	53	55	60
Intangible Assets	37	60	55	52	47	71	62	64	55	45	36
Other Noncurrent Operating Assets	25	56	54	47	45	60	73	83	82	78	99
Total Liabilities & Shareholders' Equity	493	608	623	672	727	784	841	932	971	982	1,361
Total Liabilities	464	517	472	487	511	596	603	669	689	726	1,075
Total Current Liabilities	111	109	116	143	154	157	164	191	176	204	293
Short-Term Debt	2.81	2.91	6.25	13	13	19	9.38	15	22	30	16
Accounts Payable	63	60	57	59	73	66	68	96	74	86	138
Accrued Expenses	45	46	53	71	68	72	86	80	80	89	139
Total Noncurrent Liabilities	352	409	356	344	356	439	439	478	513	521	782
Long-Term Debt	287	347	307	300	314	368	383	418	453	458	702
Other Noncurrent Operating Liabilities	66	61	50	44	43	70	56	61	60	63	79
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	30	90	151	185	216	188	239	262	283	257	286
Total Preferred & Common Equity	30	90	151	185	216	188	239	262	283	257	286
Preferred Stock	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	0.00
Total Common Equity	30	90	151	185	216	188	239	262	283	257	286
Common Stock	118	118	124	130	133	136	136	136	136	136	137
Retained Earnings	-37	34	83	132	169	183	218	248	261	244	273
Accumulated Other Comprehensive Income / (Loss)	-52	-62	-55	-76	-86	-130	-115	-121	-114	-124	-124

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	12/31/2022	3/31/2023	9/30/2023	12/31/2023	3/31/2024	9/30/2024	12/31/2024	3/31/2025	9/30/2025	12/31/2025	3/31/2026
Total Assets	962	965	965	973	979	966	1,286	1,317	1,386	1,406	1,445
Total Current Assets	582	585	584	587	597	571	746	776	836	862	894
Cash & Equivalents	68	37	43	33	50	52	67	60	73	55	55
Short-Term Investments	10	40	48	60	49	38	0.00	10	13	19	23
Accounts Receivable	152	153	149	151	161	161	192	198	218	216	222
Inventories, net	289	293	279	287	282	273	427	448	472	517	540
Other Current Assets	62	63	65	57	55	48	60	60	61	54	55
Plant, Property, & Equipment, net	186	189	193	201	202	206	338	336	355	355	359
Total Noncurrent Assets	194	191	187	185	180	189	202	205	195	188	192
Goodwill	53	53	53	55	55	55	55	55	60	60	60
Intangible Assets	59	57	52	51	48	43	40	38	35	33	32
Other Noncurrent Operating Assets	82	81	81	80	77	92	107	113	100	95	100
Total Liabilities & Shareholders' Equity	962	965	965	973	979	966	1,286	1,317	1,386	1,406	1,445
Total Liabilities	693	693	691	702	709	708	1,039	1,051	1,074	1,073	1,083
Total Current Liabilities	168	165	172	188	189	177	233	266	270	282	282
Short-Term Debt	15	15	24	26	30	7.50	16	16	18	21	23
Accounts Payable	80	76	77	86	83	87	99	132	131	133	130
Accrued Expenses	72	74	71	75	77	83	118	119	121	128	129
Total Noncurrent Liabilities	526	528	519	514	520	531	805	785	804	791	801
Long-Term Debt	461	466	459	449	456	467	737	711	725	711	713
Other Noncurrent Operating Liabilities	65	62	60	65	64	64	69	74	79	80	89
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	268	272	273	271	270	259	247	266	312	332	362
Total Preferred & Common Equity	268	272	273	271	270	259	247	266	312	332	362
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	268	272	273	271	270	259	247	266	312	332	362
Common Stock	136	136	136	136	136	136	137	137	137	138	138
Retained Earnings	249	254	248	244	248	246	244	260	294	317	336
Accumulated Other Comprehensive Income / (Loss)	-117	-118	-111	-110	-114	-124	-134	-131	-120	-122	-112

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.19%	0.39%	1.70%	7.29%	0.98%	-3.34%	4.12%	13.07%	3.78%	4.07%	27.37%
EBITDA Growth	36.14%	1.86%	6.17%	2.19%	-12.58%	-9.07%	10.31%	4.85%	-11.38%	-35.97%	125.31%
EBIT Growth	50.01%	0.31%	5.03%	1.97%	-16.70%	-17.91%	16.06%	6.12%	-17.59%	-57.56%	248.35%
NOPAT Growth	312.17%	37.73%	-14.98%	-7.24%	-12.62%	-34.33%	46.47%	-12.33%	-19.32%	-72.76%	564.51%
Net Income Growth	2,027.73%	37.24%	-21.89%	0.41%	-15.67%	-38.68%	62.09%	-9.58%	-33.69%	-92.59%	1,897.68%
EPS Growth	1,610.00%	37.09%	-22.22%	0.00%	-16.15%	-38.52%	61.45%	-9.70%	-33.06%	-92.59%	1,883.33%
Operating Cash Flow Growth	9,749.44%	-45.83%	164.35%	-28.84%	-32.62%	25.82%	-18.61%	-34.48%	-57.95%	558.11%	-8.53%
Free Cash Flow Firm Growth	226.96%	-135.36%	413.26%	-18.70%	-66.26%	-12.53%	-58.41%	-268.50%	-119.91%	301.79%	-478.87%
Invested Capital Growth	-0.95%	40.39%	0.29%	2.44%	10.15%	5.05%	11.06%	12.41%	11.91%	-6.80%	47.17%
Revenue Q/Q Growth	0.17%	0.57%	0.75%	2.11%	-0.95%	-2.20%	4.31%	3.86%	-0.02%	1.81%	8.86%
EBITDA Q/Q Growth	5.38%	3.69%	0.06%	2.96%	-10.93%	8.47%	0.44%	-3.32%	11.45%	-17.48%	19.81%
EBIT Q/Q Growth	7.03%	3.38%	0.46%	3.30%	-14.34%	11.28%	1.10%	-5.15%	17.76%	-33.44%	26.22%
NOPAT Q/Q Growth	22.16%	2.09%	4.91%	6.39%	-17.38%	-12.83%	29.03%	-7.68%	-3.93%	-60.34%	31.02%
Net Income Q/Q Growth	87.01%	6.18%	0.25%	11.59%	-19.58%	-8.61%	26.75%	-16.38%	14.03%	-81.64%	51.81%
EPS Q/Q Growth	122.06%	7.25%	-1.23%	13.38%	-20.12%	-7.78%	25.23%	-16.55%	14.08%	-81.25%	52.56%
Operating Cash Flow Q/Q Growth	110.75%	14.56%	-11.68%	-4.72%	11.25%	-15.64%	-1.64%	-4.51%	348.60%	10.32%	-8.20%
Free Cash Flow Firm Q/Q Growth	0.00%	22.48%	-11.25%	29.21%	-44.68%	-26.92%	-69.19%	54.34%	31.39%	17.58%	-6.20%
Invested Capital Q/Q Growth	0.15%	-1.18%	2.16%	-0.29%	0.56%	0.67%	6.83%	2.44%	-0.07%	-4.12%	0.46%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	31.16%	31.81%	32.48%	32.55%	31.96%	32.10%	32.56%	30.29%	30.50%	30.77%	30.85%
EBITDA Margin	15.45%	15.67%	16.36%	15.59%	13.49%	12.69%	13.45%	12.47%	10.65%	6.55%	11.59%
Operating Margin	11.71%	11.41%	12.81%	12.06%	10.05%	8.65%	8.98%	8.38%	7.35%	5.24%	8.52%
EBIT Margin	12.43%	12.42%	12.83%	12.19%	10.06%	8.54%	9.52%	8.94%	7.10%	2.89%	7.92%
Profit (Net Income) Margin	8.05%	11.01%	8.45%	7.91%	6.61%	4.19%	6.53%	5.22%	3.33%	0.24%	3.72%
Tax Burden Percent	76.53%	107.77%	80.22%	73.67%	76.52%	60.44%	81.82%	67.99%	60.30%	22.13%	70.98%
Interest Burden Percent	84.63%	82.23%	82.15%	88.09%	85.86%	81.20%	83.77%	85.90%	77.92%	37.06%	66.27%
Effective Tax Rate	23.47%	-7.77%	19.78%	26.33%	23.48%	39.56%	18.18%	32.01%	39.70%	77.87%	29.02%
Return on Invested Capital (ROIC)	23.03%	26.52%	19.27%	17.64%	14.49%	8.86%	12.00%	9.41%	6.77%	1.81%	10.07%
ROIC Less NNEP Spread (ROIC-NNEP)	20.50%	23.16%	14.41%	14.38%	10.74%	5.79%	9.68%	8.00%	3.85%	-0.64%	4.13%
Return on Net Nonoperating Assets (RNNOA)	246.21%	111.24%	34.21%	20.97%	12.80%	7.75%	13.49%	10.22%	5.20%	-0.91%	7.73%
Return on Equity (ROE)	269.25%	137.76%	53.48%	38.61%	27.29%	16.60%	25.49%	19.63%	11.97%	0.90%	17.80%
Cash Return on Invested Capital (CROIC)	23.99%	-7.09%	18.99%	15.23%	4.83%	3.93%	1.51%	-2.28%	-4.47%	8.84%	-28.10%
Operating Return on Assets (OROA)	19.28%	16.96%	15.93%	15.44%	11.91%	9.05%	9.76%	9.50%	7.29%	3.02%	8.76%
Return on Assets (ROA)	12.49%	15.03%	10.50%	10.02%	7.83%	4.44%	6.69%	5.55%	3.43%	0.25%	4.12%
Return on Common Equity (ROCE)	269.25%	137.76%	53.48%	38.61%	27.29%	16.60%	25.49%	19.63%	11.97%	0.90%	17.80%
Return on Equity Simple (ROE_SIMPLE)	203.46%	91.43%	42.75%	35.08%	25.33%	17.83%	22.80%	18.74%	11.54%	0.94%	0.00%
Net Operating Profit after Tax (NOPAT)	67	92	79	73	64	42	61	54	43	12	78
NOPAT Margin	8.96%	12.30%	10.28%	8.89%	7.69%	5.23%	7.35%	5.70%	4.43%	1.16%	6.05%
Net Nonoperating Expense Percent (NNEP)	2.53%	3.36%	4.86%	3.26%	3.75%	3.06%	2.31%	1.41%	2.92%	2.45%	5.94%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-	7.81%
Cost of Revenue to Revenue	68.84%	68.19%	67.52%	67.45%	68.04%	67.90%	67.44%	69.71%	69.50%	69.23%	69.15%
SG&A Expenses to Revenue	19.45%	20.40%	19.67%	20.48%	21.91%	23.45%	23.58%	21.91%	23.15%	25.53%	22.33%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	19.45%	20.40%	19.67%	20.48%	21.91%	23.45%	23.58%	21.91%	23.15%	25.53%	22.33%
Earnings before Interest and Taxes (EBIT)	93	93	98	100	83	68	79	84	69	29	103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	116	118	125	128	112	102	112	117	104	67	150
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	42.50	6.83	8.29	8.65	5.20	5.04	4.47	2.75	1.90	2.65	3.62
Price to Tangible Book Value (P/TBV)	0.00	66.76	17.26	15.15	7.95	14.69	8.63	4.97	3.07	4.33	5.46
Price to Revenue (P/Rev)	1.68	0.82	1.64	1.95	1.36	1.18	1.28	0.77	0.55	0.67	0.80
Price to Earnings (P/E)	20.89	7.48	19.38	24.66	20.53	28.25	19.60	14.68	16.42	281.14	21.45
Dividend Yield	1.24%	2.55%	1.27%	1.01%	1.66%	2.05%	1.82%	2.69%	3.63%	2.86%	1.88%
Earnings Yield	4.79%	13.38%	5.16%	4.05%	4.87%	3.54%	5.10%	6.81%	6.09%	0.36%	4.66%
Enterprise Value to Invested Capital (EV/IC)	5.24	2.30	3.70	4.38	2.97	2.57	2.54	1.76	1.37	1.67	1.81
Enterprise Value to Revenue (EV/Rev)	2.03	1.24	1.98	2.24	1.65	1.55	1.64	1.13	0.95	1.03	1.29
Enterprise Value to EBITDA (EV/EBITDA)	13.14	7.94	12.07	14.35	12.24	12.24	12.18	9.05	8.92	15.79	11.16
Enterprise Value to EBIT (EV/EBIT)	16.33	10.02	15.40	18.34	16.42	18.19	17.20	12.63	13.39	35.74	16.34
Enterprise Value to NOPAT (EV/NOPAT)	22.64	10.12	19.21	25.16	21.48	29.73	22.28	19.81	21.44	89.21	21.39
Enterprise Value to Operating Cash Flow (EV/OCF)	22.11	25.12	15.34	26.19	29.00	20.95	28.25	33.61	69.79	12.02	20.93
Enterprise Value to Free Cash Flow (EV/FCFF)	21.74	0.00	19.50	29.14	64.42	66.95	176.70	0.00	0.00	18.23	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	9.77	3.87	2.07	1.69	1.51	2.06	1.64	1.65	1.68	1.90	2.52
Long-Term Debt to Equity	9.68	3.84	2.03	1.62	1.45	1.96	1.60	1.59	1.60	1.79	2.46
Financial Leverage	12.01	4.80	2.37	1.46	1.19	1.34	1.39	1.28	1.35	1.42	1.87
Leverage Ratio	21.57	9.17	5.10	3.85	3.49	3.74	3.81	3.54	3.49	3.62	4.32
Compound Leverage Factor	18.25	7.54	4.19	3.39	2.99	3.03	3.19	3.04	2.72	1.34	2.86
Debt to Total Capital	90.72%	79.47%	67.44%	62.81%	60.16%	67.28%	62.18%	62.26%	62.70%	65.54%	71.56%
Short-Term Debt to Total Capital	0.88%	0.66%	1.35%	2.53%	2.31%	3.26%	1.49%	2.16%	2.94%	4.00%	1.62%
Long-Term Debt to Total Capital	89.84%	78.81%	66.10%	60.28%	57.85%	64.02%	60.69%	60.10%	59.75%	61.54%	69.94%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	9.28%	20.53%	32.56%	37.19%	39.84%	32.72%	37.82%	37.74%	37.30%	34.46%	28.44%
Debt to EBITDA	2.50	2.97	2.50	2.44	2.92	3.81	3.50	3.68	4.56	7.32	4.78
Net Debt to EBITDA	2.25	2.69	2.06	1.82	2.19	2.91	2.67	2.91	3.78	5.60	4.27
Long-Term Debt to EBITDA	2.48	2.95	2.45	2.35	2.81	3.62	3.42	3.56	4.35	6.87	4.68
Debt to NOPAT	4.32	3.79	3.99	4.29	5.12	9.25	6.40	8.06	10.96	41.36	9.17
Net Debt to NOPAT	3.88	3.43	3.27	3.20	3.84	7.07	4.88	6.36	9.08	31.65	8.18
Long-Term Debt to NOPAT	4.27	3.76	3.91	4.11	4.93	8.81	6.25	7.78	10.45	38.84	8.96
Altman Z-Score	4.16	3.00	4.00	4.45	3.68	3.04	3.20	2.81	2.59	2.53	2.52
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.82	3.15	3.14	2.90	3.02	2.87	3.04	2.97	3.33	2.94	2.76
Quick Ratio	1.26	1.45	1.57	1.50	1.56	1.39	1.46	1.35	1.39	1.39	1.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	70	-25	77	63	21	19	7.72	-13	-29	58	-219
Operating Cash Flow to CapEx	342.53%	102.38%	471.19%	377.44%	157.80%	174.32%	164.75%	85.44%	25.70%	212.41%	209.24%
Free Cash Flow to Firm to Interest Expense	4.89	-1.49	4.42	5.28	1.80	1.44	0.60	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	4.80	2.24	5.62	5.88	4.01	4.62	3.75	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	3.40	0.05	4.43	4.32	1.47	1.97	1.47	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.55	1.37	1.24	1.27	1.18	1.06	1.03	1.06	1.03	1.04	1.11
Accounts Receivable Turnover	6.66	6.40	6.12	6.27	5.62	5.61	6.10	6.01	5.93	6.11	6.52
Inventory Turnover	3.52	3.23	3.14	3.26	2.99	2.75	2.72	2.76	2.53	2.59	2.52
Fixed Asset Turnover	7.01	6.49	6.00	6.37	6.13	5.55	5.50	5.89	5.42	5.10	4.65
Accounts Payable Turnover	8.40	8.32	8.82	9.50	8.49	7.80	8.36	8.01	8.02	8.84	8.01
Days Sales Outstanding (DSO)	54.84	57.04	59.61	58.22	64.97	65.11	59.87	60.70	61.59	59.70	55.96
Days Inventory Outstanding (DIO)	103.76	113.05	116.33	111.99	121.96	132.64	134.11	132.10	144.12	140.77	144.64
Days Payable Outstanding (DPO)	43.44	43.88	41.40	38.40	42.98	46.77	43.66	45.55	45.50	41.29	45.56
Cash Conversion Cycle (CCC)	115.16	126.21	134.54	131.80	143.95	150.98	150.32	147.25	160.21	159.18	155.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	290	407	408	418	461	484	537	604	676	630	927
Invested Capital Turnover	2.57	2.16	1.87	1.98	1.88	1.69	1.63	1.65	1.53	1.56	1.66
Increase / (Decrease) in Invested Capital	-2.79	117	1.17	9.95	42	23	54	67	72	-46	297
Enterprise Value (EV)	1,519	935	1,510	1,834	1,368	1,243	1,365	1,064	929	1,053	1,677
Market Capitalization	1,259	618	1,252	1,600	1,123	948	1,066	722	535	679	1,035
Book Value per Share	$0.76	$2.30	$3.81	$4.59	$5.34	$4.65	$5.89	$6.48	$6.97	$6.34	$7.05
Tangible Book Value per Share	($0.52)	$0.24	$1.83	$2.62	$3.49	$1.60	$3.05	$3.59	$4.30	$3.88	$4.68
Total Capital	319	441	464	497	542	575	631	695	757	745	1,004
Total Debt	290	350	313	312	326	387	392	433	475	488	719
Total Long-Term Debt	287	347	307	300	314	368	383	418	453	458	702
Net Debt	260	317	257	233	245	296	299	342	394	373	642
Capital Expenditures (CapEx)	20	36	21	19	30	34	29	37	52	41	38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	176	203	198	206	243	222	251	299	351	312	456
Debt-free Net Working Capital (DFNWC)	205	237	254	285	324	313	344	390	432	427	533
Net Working Capital (NWC)	202	234	248	272	312	295	335	375	410	397	517
Net Nonoperating Expense (NNE)	6.82	9.68	14	8.00	8.97	8.27	6.87	4.53	11	9.38	30
Net Nonoperating Obligations (NNO)	260	317	257	233	245	296	299	342	394	373	642
Total Depreciation and Amortization (D&A)	23	24	27	28	28	33	33	33	35	37	48
Debt-free, Cash-free Net Working Capital to Revenue	23.51%	27.06%	25.91%	25.08%	29.34%	27.74%	30.11%	31.75%	35.87%	30.66%	35.21%
Debt-free Net Working Capital to Revenue	27.41%	31.53%	33.25%	34.73%	39.19%	39.15%	41.30%	41.43%	44.18%	41.92%	41.15%
Net Working Capital to Revenue	27.04%	31.14%	32.43%	33.20%	37.67%	36.81%	40.17%	39.84%	41.90%	39.00%	39.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.55	$2.11	$1.63	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06	$1.19
Adjusted Weighted Average Basic Shares Outstanding	38.97M	39.25M	39.52M	40.18M	40.41M	40.45M	40.47M	40.50M	40.50M	40.50M	40.52M
Adjusted Diluted Earnings per Share	$1.51	$2.07	$1.61	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06	$1.19
Adjusted Weighted Average Diluted Shares Outstanding	39.82M	39.96M	40.04M	40.39M	40.52M	40.50M	40.50M	40.50M	40.50M	40.52M	40.68M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.10M	39.41M	39.89M	40.37M	40.45M	40.45M	40.50M	40.50M	40.50M	40.50M	40.53M
Normalized Net Operating Profit after Tax (NOPAT)	67	60	79	73	64	42	61	54	43	37	78
Normalized NOPAT Margin	8.96%	7.99%	10.28%	8.89%	7.69%	5.23%	7.35%	5.70%	4.43%	3.67%	6.05%
Pre Tax Income Margin	10.52%	10.21%	10.54%	10.74%	8.64%	6.94%	7.98%	7.68%	5.53%	1.07%	5.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	6.51	5.63	5.60	8.39	7.07	5.32	6.16	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	4.69	5.57	4.49	6.12	5.41	3.25	4.76	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	5.10	3.44	4.41	6.84	4.53	2.67	3.88	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	3.29	3.38	3.30	4.56	2.87	0.60	2.48	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	25.87%	18.99%	24.49%	24.77%	33.98%	57.87%	35.73%	39.54%	59.63%	804.72%	40.30%
Augmented Payout Ratio	25.87%	18.99%	24.49%	24.77%	33.98%	57.87%	35.73%	39.54%	59.63%	804.72%	40.30%

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	40,534,716.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	40,534,716.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.59
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.50%	2.17%	7.14%	7.10%	12.57%	23.73%	32.14%	38.63%	39.73%	20.90%	10.27%
EBITDA Growth	-89.95%	-29.50%	-2.53%	-40.66%	1,451.98%	48.97%	93.79%	120.51%	131.78%	137.90%	6.76%
EBIT Growth	-187.40%	-48.58%	-7.79%	-57.03%	332.78%	68.22%	123.14%	191.20%	179.97%	248.28%	9.48%
NOPAT Growth	-105.22%	-40.52%	5.06%	-83.04%	2,625.13%	199.58%	81.89%	1,026.86%	192.17%	125.70%	40.84%
Net Income Growth	-307.86%	-82.33%	-16.30%	-93.46%	187.02%	150.00%	148.42%	2,190.43%	280.32%	762.14%	15.06%
EPS Growth	-300.00%	-83.33%	-16.00%	-92.86%	185.00%	166.67%	142.86%	2,050.00%	282.35%	737.50%	15.69%
Operating Cash Flow Growth	251.42%	1,367.90%	82.27%	40.47%	-22.08%	-90.25%	278.28%	-25.18%	-26.30%	529.13%	-62.45%
Free Cash Flow Firm Growth	76.59%	116.51%	143.40%	181.27%	260.49%	-1,514.88%	-849.71%	-667.13%	-931.52%	93.04%	73.73%
Invested Capital Growth	3.29%	-1.95%	-2.86%	-6.80%	-3.30%	42.81%	40.46%	47.17%	50.79%	6.03%	10.49%
Revenue Q/Q Growth	-9.29%	8.04%	5.31%	3.78%	-4.66%	18.75%	12.47%	8.88%	-3.91%	2.75%	2.58%
EBITDA Q/Q Growth	-95.06%	913.64%	54.96%	-23.54%	29.24%	-2.70%	101.57%	-13.00%	35.85%	-0.14%	-9.54%
EBIT Q/Q Growth	-128.59%	210.91%	112.76%	-36.30%	54.86%	-19.85%	182.23%	-16.87%	48.89%	-0.30%	-11.28%
NOPAT Q/Q Growth	-103.99%	1,204.09%	130.97%	-83.32%	493.78%	30.99%	40.23%	3.32%	53.95%	1.19%	-12.49%
Net Income Q/Q Growth	-169.71%	115.90%	559.73%	-91.05%	827.53%	-54.34%	555.57%	-17.51%	54.01%	3.51%	-12.51%
EPS Q/Q Growth	-171.43%	115.00%	600.00%	-90.48%	750.00%	-52.94%	537.50%	-15.69%	51.16%	3.08%	-11.94%
Operating Cash Flow Q/Q Growth	-19.96%	94.81%	-63.85%	149.20%	-55.60%	-75.63%	1,302.93%	-50.71%	-56.27%	108.04%	-16.26%
Free Cash Flow Firm Q/Q Growth	63.42%	185.78%	73.98%	48.86%	-27.76%	-856.21%	7.81%	-12.61%	-5.92%	93.67%	-247.87%
Invested Capital Q/Q Growth	-1.67%	-1.74%	0.61%	-4.12%	2.02%	45.11%	-1.05%	0.46%	4.53%	2.03%	3.11%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	29.27%	31.45%	30.24%	31.90%	32.06%	32.94%	30.06%	29.05%	32.92%	35.48%	32.77%
EBITDA Margin	0.74%	6.96%	10.24%	7.54%	10.23%	8.38%	15.02%	12.00%	16.96%	16.49%	14.54%
Operating Margin	-0.31%	6.28%	7.57%	6.74%	6.80%	8.26%	9.64%	8.90%	14.09%	13.46%	11.64%
EBIT Margin	-3.21%	3.29%	6.65%	4.08%	6.63%	4.47%	11.22%	8.57%	13.28%	12.89%	11.14%
Profit (Net Income) Margin	-3.46%	0.51%	3.19%	0.28%	2.68%	1.03%	6.00%	4.55%	7.29%	7.34%	6.26%
Tax Burden Percent	66.91%	35.74%	65.04%	11.74%	72.51%	65.83%	70.33%	72.23%	73.14%	75.39%	74.35%
Interest Burden Percent	161.55%	43.35%	73.85%	57.49%	55.73%	34.97%	76.04%	73.47%	75.05%	75.60%	75.60%
Effective Tax Rate	0.00%	64.26%	34.96%	88.26%	27.49%	34.17%	29.67%	27.77%	26.86%	24.62%	25.65%
Return on Invested Capital (ROIC)	-0.33%	3.34%	7.38%	1.23%	7.89%	7.58%	10.21%	10.70%	17.89%	15.46%	13.37%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.27%	2.23%	6.23%	0.87%	6.38%	5.03%	9.70%	9.30%	15.79%	13.90%	11.97%
Return on Net Nonoperating Assets (RNNOA)	-3.27%	3.23%	9.09%	1.23%	9.31%	10.38%	18.89%	17.41%	28.85%	32.23%	25.07%
Return on Equity (ROE)	-3.60%	6.57%	16.47%	2.46%	17.20%	17.97%	29.10%	28.11%	46.74%	47.69%	38.44%
Cash Return on Invested Capital (CROIC)	1.73%	6.53%	7.37%	8.84%	9.23%	-29.38%	-26.08%	-28.10%	-27.70%	6.96%	3.72%
Operating Return on Assets (OROA)	-3.27%	3.34%	6.83%	4.25%	7.19%	4.38%	11.64%	9.48%	15.81%	14.02%	12.10%
Return on Assets (ROA)	-3.54%	0.52%	3.28%	0.29%	2.90%	1.01%	6.23%	5.03%	8.68%	7.99%	6.80%
Return on Common Equity (ROCE)	-3.60%	6.57%	16.47%	2.46%	17.20%	17.97%	29.10%	28.11%	46.74%	47.69%	38.44%
Return on Equity Simple (ROE_SIMPLE)	7.59%	5.46%	4.87%	0.00%	6.73%	7.83%	11.95%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.51	5.61	13	2.16	13	17	24	24	37	38	33
NOPAT Margin	-0.22%	2.24%	4.92%	0.79%	4.93%	5.44%	6.78%	6.43%	10.30%	10.15%	8.66%
Net Nonoperating Expense Percent (NNEP)	1.94%	1.11%	1.15%	0.37%	1.51%	2.55%	0.52%	1.40%	2.10%	1.56%	1.40%
Return On Investment Capital (ROIC_SIMPLE)	-	0.75%	-	-	-	1.68%	2.37%	2.42%	3.56%	3.57%	3.03%
Cost of Revenue to Revenue	70.73%	68.55%	69.76%	68.10%	67.94%	67.06%	69.94%	70.95%	67.08%	64.52%	67.23%
SG&A Expenses to Revenue	29.59%	25.17%	22.67%	25.16%	25.26%	24.68%	20.43%	20.15%	18.83%	22.02%	21.12%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	29.59%	25.17%	22.67%	25.16%	25.26%	24.68%	20.43%	20.15%	18.83%	22.02%	21.12%
Earnings before Interest and Taxes (EBIT)	-7.42	8.22	17	11	17	14	39	32	48	48	43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1.72	17	27	21	27	26	52	45	62	62	56
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.83	1.69	1.93	2.65	3.53	3.45	3.25	3.62	5.26	4.56	6.20
Price to Tangible Book Value (P/TBV)	2.98	2.76	3.11	4.33	5.67	5.58	4.98	5.46	7.56	6.32	8.30
Price to Revenue (P/Rev)	0.51	0.46	0.52	0.67	0.87	0.77	0.73	0.80	1.17	1.03	1.49
Price to Earnings (P/E)	24.12	30.85	39.51	281.14	52.40	44.03	27.21	21.45	24.18	16.44	23.54
Dividend Yield	3.89%	4.26%	3.74%	2.86%	2.13%	2.29%	2.25%	1.88%	1.19%	1.28%	0.87%
Earnings Yield	4.15%	3.24%	2.53%	0.36%	1.91%	2.27%	3.67%	4.66%	4.14%	6.08%	4.25%
Enterprise Value to Invested Capital (EV/IC)	1.34	1.28	1.38	1.67	2.02	1.65	1.65	1.81	2.37	2.20	2.84
Enterprise Value to Revenue (EV/Rev)	0.91	0.85	0.91	1.03	1.24	1.39	1.28	1.29	1.64	1.48	1.93
Enterprise Value to EBITDA (EV/EBITDA)	10.05	10.30	11.23	15.79	14.16	15.35	12.14	11.16	12.40	9.82	12.91
Enterprise Value to EBIT (EV/EBIT)	16.67	18.35	20.50	35.74	23.95	25.72	18.73	16.34	17.19	12.92	16.89
Enterprise Value to NOPAT (EV/NOPAT)	27.47	27.83	30.49	89.21	33.76	32.95	25.44	21.39	22.26	17.63	21.80
Enterprise Value to Operating Cash Flow (EV/OCF)	22.18	11.30	11.42	12.02	15.43	27.67	17.44	20.93	29.92	23.32	43.85
Enterprise Value to Free Cash Flow (EV/FCFF)	78.76	19.46	18.47	18.23	21.49	0.00	0.00	0.00	0.00	32.44	80.20
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.77	1.75	1.80	1.90	1.83	3.05	2.73	2.52	2.38	2.20	2.03
Long-Term Debt to Equity	1.68	1.66	1.69	1.79	1.81	2.99	2.67	2.46	2.32	2.14	1.97
Financial Leverage	1.44	1.45	1.46	1.42	1.46	2.06	1.95	1.87	1.83	2.32	2.09
Leverage Ratio	3.57	3.59	3.58	3.62	3.63	4.36	4.28	4.32	4.12	4.65	4.40
Compound Leverage Factor	5.77	1.56	2.65	2.08	2.02	1.53	3.26	3.17	3.10	3.51	3.33
Debt to Total Capital	63.88%	63.68%	64.27%	65.54%	64.72%	75.32%	73.22%	71.56%	70.45%	68.75%	67.03%
Short-Term Debt to Total Capital	3.19%	3.49%	3.94%	4.00%	1.02%	1.63%	1.64%	1.62%	1.75%	1.94%	2.08%
Long-Term Debt to Total Capital	60.68%	60.19%	60.33%	61.54%	63.69%	73.69%	71.59%	69.94%	68.70%	66.81%	64.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	36.12%	36.32%	35.73%	34.46%	35.28%	24.68%	26.78%	28.44%	29.55%	31.25%	32.97%
Debt to EBITDA	5.44	5.83	6.01	7.32	5.18	7.52	5.80	4.78	4.01	3.31	3.28
Net Debt to EBITDA	4.41	4.69	4.79	5.60	4.20	6.85	5.24	4.27	3.55	2.97	2.93
Long-Term Debt to EBITDA	5.17	5.51	5.64	6.87	5.10	7.36	5.67	4.68	3.91	3.21	3.17
Debt to NOPAT	14.87	15.76	16.33	41.36	12.35	16.15	12.15	9.17	7.20	5.94	5.53
Net Debt to NOPAT	12.06	12.69	13.01	31.65	10.01	14.71	10.98	8.18	6.37	5.33	4.95
Long-Term Debt to NOPAT	14.13	14.89	15.32	38.84	12.15	15.80	11.88	8.96	7.02	5.77	5.36
Altman Z-Score	2.29	2.27	2.37	2.47	2.76	2.13	2.24	2.35	2.83	2.81	3.21
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.39	3.12	3.16	2.94	3.23	3.20	2.91	2.76	3.09	3.05	3.17
Quick Ratio	1.39	1.30	1.37	1.39	1.42	1.11	1.01	1.04	1.12	1.03	1.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-22	19	32	48	35	-263	-242	-273	-289	-18	-64
Operating Cash Flow to CapEx	216.68%	287.96%	117.23%	217.48%	131.71%	39.33%	557.11%	161.86%	67.38%	174.39%	105.81%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	7.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	2.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.02	1.02	1.03	1.04	1.08	0.98	1.04	1.11	1.19	1.09	1.09
Accounts Receivable Turnover	6.69	6.49	6.37	6.11	6.75	6.46	6.64	6.52	7.39	7.18	7.16
Inventory Turnover	2.43	2.37	2.42	2.59	2.60	2.11	2.23	2.52	2.59	2.11	2.05
Fixed Asset Turnover	5.24	5.08	5.11	5.10	5.24	4.11	4.43	4.65	4.99	4.23	4.31
Accounts Payable Turnover	8.21	8.19	8.80	8.84	8.77	8.11	7.60	8.01	8.87	8.57	7.75
Days Sales Outstanding (DSO)	54.55	56.21	57.30	59.70	54.05	56.50	54.96	55.96	49.37	50.81	50.98
Days Inventory Outstanding (DIO)	150.43	153.71	150.60	140.77	140.25	172.80	163.90	144.64	140.99	172.85	178.20
Days Payable Outstanding (DPO)	44.48	44.57	41.47	41.29	41.63	44.99	48.06	45.56	41.13	42.59	47.12
Cash Conversion Cycle (CCC)	160.50	165.36	166.42	159.18	152.67	184.31	170.81	155.03	149.24	181.07	182.07
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	665	653	657	630	643	933	923	927	969	989	1,020
Invested Capital Turnover	1.49	1.49	1.50	1.56	1.60	1.39	1.51	1.66	1.74	1.52	1.54
Increase / (Decrease) in Invested Capital	21	-13	-19	-46	-22	280	266	297	327	56	97
Enterprise Value (EV)	892	839	907	1,053	1,296	1,537	1,522	1,677	2,298	2,171	2,900
Market Capitalization	500	457	520	679	912	851	865	1,035	1,640	1,514	2,242
Book Value per Share	$6.74	$6.69	$6.67	$6.34	$6.38	$6.09	$6.57	$7.05	$7.69	$8.20	$8.93
Tangible Book Value per Share	$4.14	$4.08	$4.13	$3.88	$3.98	$3.76	$4.29	$4.68	$5.35	$5.91	$6.67
Total Capital	756	746	756	745	733	1,000	993	1,004	1,055	1,064	1,097
Total Debt	483	475	486	488	474	753	727	719	743	731	736
Total Long-Term Debt	459	449	456	458	467	737	711	702	725	711	713
Net Debt	392	382	387	373	384	686	657	642	658	657	658
Capital Expenditures (CapEx)	7.48	11	9.73	13	9.58	7.82	7.75	13	14	11	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	345	332	339	312	312	462	455	456	499	526	558
Debt-free Net Working Capital (DFNWC)	436	425	438	427	401	529	526	533	584	600	635
Net Working Capital (NWC)	412	399	408	397	394	513	510	517	566	580	612
Net Nonoperating Expense (NNE)	7.51	4.34	4.55	1.41	5.86	14	2.69	7.13	11	10	9.17
Net Nonoperating Obligations (NNO)	392	382	387	373	384	686	657	642	658	657	658
Total Depreciation and Amortization (D&A)	9.13	9.17	9.46	9.46	9.37	12	13	13	13	13	13
Debt-free, Cash-free Net Working Capital to Revenue	35.33%	33.85%	33.93%	30.66%	29.76%	41.78%	38.25%	35.21%	35.64%	35.92%	37.17%
Debt-free Net Working Capital to Revenue	44.66%	43.27%	43.81%	41.92%	38.34%	47.84%	44.16%	41.15%	41.73%	41.01%	42.33%
Net Working Capital to Revenue	42.19%	40.62%	40.83%	39.00%	37.63%	46.37%	42.79%	39.90%	40.41%	39.60%	40.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08	$0.52	$0.42	$0.65	$0.68	$0.59
Adjusted Weighted Average Basic Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.52M	40.52M	40.53M	40.53M	40.55M
Adjusted Diluted Earnings per Share	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08	$0.51	$0.43	$0.65	$0.67	$0.59
Adjusted Weighted Average Diluted Shares Outstanding	40.50M	40.50M	40.52M	40.52M	40.58M	40.72M	40.71M	40.68M	40.88M	40.96M	41.04M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.53M	40.53M	40.53M	40.53M	40.56M
Normalized Net Operating Profit after Tax (NOPAT)	-0.51	11	13	13	13	17	24	24	37	38	33
Normalized NOPAT Margin	-0.22%	4.40%	4.92%	4.72%	4.93%	5.44%	6.78%	6.43%	10.30%	10.15%	8.66%
Pre Tax Income Margin	-5.18%	1.43%	4.91%	2.35%	3.69%	1.56%	8.54%	6.30%	9.97%	9.74%	8.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	3.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	2.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	1.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	93.76%	131.38%	147.71%	804.72%	111.70%	100.64%	61.17%	40.30%	28.69%	21.13%	20.43%
Augmented Payout Ratio	93.76%	131.38%	147.71%	804.72%	111.70%	100.64%	61.17%	40.30%	28.69%	21.13%	20.43%

Financials Breakdown Chart

Key Financial Trends

Phibro Animal Health (PAHC) has shown a pattern of revenue growth in newer quarters, improving profitability in the latest reported period, and a solid near-term liquidity position. Here are the key takeaways from PAHC’s quarterly statements over the last four years.

Significant quarterly revenue growth in the latest period: Q2 2026 Operating Revenue of $373.91 million, up from $309.26 million in Q2 2025 (about +21% YoY).
Net income improved meaningfully: Q2 2026 Consolidated Net Income / (Loss) attributable to common shareholders to $27.46 million, versus $3.19 million in Q2 2025.
Earnings per share trending higher: Q2 2026 Diluted EPS of $0.67 and Basic EPS of $0.68, up modestly versus peers in the prior year.
Free cash flow was positive in Q2 2026: roughly $2.2 million, after accounting for operating cash flow (~$19.35 million) and investing cash outlays (net investing activities around -$17.18 million).
Strong near-term liquidity: Total current assets of $862.19 million vs. Total current liabilities of $282.37 million, providing a current ratio around 3.05x.
Gross margin has fluctuated in the 29%–36% range in recent quarters (example: Q2 2026 gross margin ≈ 35.5%; Q4 2025 ≈ 29.0%; Q1 2026 ≈ 32.9%), indicating variability but generally solid profitability.
Dividend per share is stable: cash dividends per share remained at $0.12 in the latest periods, suggesting consistent capital return to shareholders.
Working capital levels are elevated, with inventories at approximately $517 million and accounts receivable around $216 million in Q2 2026, supporting current operations but contributing to higher working capital needs.
Leverage stress from debt load: Long-term debt of about $710.6 million and Total Liabilities around $1.073 billion with Total Equity near $332 million, signaling a leveraged balance sheet.
Financing activity often results in cash outflows: Net cash from financing activities in Q2 2026 is negative (about -$18.98 million), reflecting a mix of debt issuance, repayments, and dividends, which may indicate ongoing funding needs.

05/18/26 08:48 PM ETAI Generated. May Contain Errors.

Phibro Animal Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Phibro Animal Health's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

Phibro Animal Health's net income appears to be on a downward trend, with a most recent value of $48.26 million in 2025, falling from $60.28 million in 2015. The previous period was $2.42 million in 2024. Check out Phibro Animal Health's forecast to explore projected trends and price targets.

Phibro Animal Health's total operating income in 2025 was $110.47 million, based on the following breakdown:

Total Gross Profit: $399.94 million
Total Operating Expenses: $289.48 million

Over the last 10 years, Phibro Animal Health's total revenue changed from $748.59 million in 2015 to $1.30 billion in 2025, a change of 73.2%.

Phibro Animal Health's total liabilities were at $1.08 billion at the end of 2025, a 48.2% increase from 2024, and a 131.9% increase since 2015.

In the past 10 years, Phibro Animal Health's cash and equivalents has ranged from $29.17 million in 2018 to $74.25 million in 2022, and is currently $68.04 million as of their latest financial filing in 2025.

Over the last 10 years, Phibro Animal Health's book value per share changed from 0.76 in 2015 to 7.05 in 2025, a change of 828.0%.

Related Companies

Financial statements for NASDAQ:PAHC last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Financials

Financials Breakdown Chart

Key Financial Trends

Phibro Animal Health Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Financials

Annual Income Statements for Phibro Animal Health

Quarterly Income Statements for Phibro Animal Health

Annual Cash Flow Statements for Phibro Animal Health

Quarterly Cash Flow Statements for Phibro Animal Health

Annual Balance Sheets for Phibro Animal Health

Quarterly Balance Sheets for Phibro Animal Health

Annual Metrics And Ratios for Phibro Animal Health

Quarterly Metrics And Ratios for Phibro Animal Health

Financials Breakdown Chart

Key Financial Trends

Phibro Animal Health Financials - Frequently Asked Questions

When does Phibro Animal Health's financial year end?

How has Phibro Animal Health's net income changed over the last 10 years?

What is Phibro Animal Health's operating income?

How has Phibro Animal Health's revenue changed over the last 10 years?

How much debt does Phibro Animal Health have?

How much cash does Phibro Animal Health have?

How has Phibro Animal Health's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools